Context Therapeutics Inc. – NASDAQ:CNTX
Founder-led company
Context Therapeutics stock price today
$0.877
-0.22
-20.25%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 1 day
Context Therapeutics stock price monthly change
-45.55%
month
Context Therapeutics stock price quarterly change
-45.55%
quarter
Context Therapeutics stock price yearly change
-3.51%
year
Context Therapeutics key metrics
Market Cap | 76.87M |
Enterprise value | N/A |
P/E | -0.17 |
EV/Sales | N/A |
EV/EBITDA | 1.19 |
Price/Sales | N/A |
Price/Book | 0.27 |
PEG ratio | N/A |
EPS | -1.33 |
Revenue | N/A |
EBITDA | -22.21M |
Income | -21.32M |
Revenue Q/Q | N/A |
Revenue Y/Y | N/A |
Profit margin | 0% |
Oper. margin | 0% |
Gross margin | 0% |
EBIT margin | 0% |
EBITDA margin | N/A |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeContext Therapeutics stock price history
Context Therapeutics stock forecast
Context Therapeutics financial statements
| Jun 2023 | 0 | -5.01M | |
|---|---|---|---|
| Sep 2023 | 0 | -5.87M | |
| Dec 2023 | 18.95K | -6.76M | -35721.22% |
| Mar 2024 | 0 | -3.66M |
| Dec 2023 | 18.95K | -6.76M | -35721.22% |
|---|---|---|---|
| Mar 2024 | 0 | -3.66M | |
| Oct 2025 | 0 | -1.11M | |
| Dec 2025 | 0 | -1.11M |
Analysts Price target
Financials & Ratios estimates
| 2024-03-21 | -0.35 | -0.42 |
|---|---|---|
| 2024-05-08 | -0.38 | -0.23 |
| Jun 2023 | 27762042 | 3.75M | 13.53% |
|---|---|---|---|
| Sep 2023 | 22988623 | 4.60M | 20.03% |
| Dec 2023 | 16062735 | 4.19M | 26.1% |
| Mar 2024 | 11051652 | 2.60M | 23.6% |
| Jun 2023 | -4.63M | 0 | 0 |
|---|---|---|---|
| Sep 2023 | -3.46M | 0 | 0 |
| Dec 2023 | -7.22M | 0 | 0 |
| Mar 2024 | -4.36M | 0 | 0 |
Context Therapeutics alternative data
| Aug 2023 | 9 |
|---|---|
| Sep 2023 | 9 |
| Oct 2023 | 9 |
| Nov 2023 | 9 |
| Dec 2023 | 9 |
| Jan 2024 | 9 |
| Feb 2024 | 9 |
| Mar 2024 | 5 |
| Apr 2024 | 5 |
| May 2024 | 5 |
| Jun 2024 | 5 |
| Jul 2024 | 5 |
Context Therapeutics other data
1.32%
-23.00%
of CNTX is owned by hedge funds
211.05K
-3.67M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2022 | 38000 | 0 |
| Dec 2022 | 51000 | 0 |
| Jan 2023 | 20649 | 0 |
| Feb 2023 | 16469 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 5,823 | $0.84 | $4,903 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 5,606 | $0.87 | $4,900 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 5,040 | $0.97 | $4,899 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 7,027 | $0.7 | $4,898 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 6,839 | $0.72 | $4,904 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 6,783 | $0.74 | $4,992 | ||
Purchase | MINAI-AZARY JENNIFER LYNN officer: Chief Financial Officer | Common Stock | 25,000 | $0.74 | $18,500 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 20,000 | $0.74 | $14,800 | ||
Purchase | LEVIT ALEX C. officer: Chief Legal Officer, C.. | Common Stock | 6,000 | $0.85 | $5,094 | ||
Purchase | LEHR MARTIN A. director, officer.. | Common Stock | 13,000 | $1.85 | $24,063 |
| Insider | Compensation |
|---|---|
| Mr. Martin A. Lehr (1984) Co-Founder, Chief Executive Officer & Director | $250,000 |
Dr. William F. Rencher Ph.D. (1959) Head of CMC & Regulatory | $246,470 |
Dr. Tarek Sahmoud M.D., Ph.D. (1961) Chief Medical Officer | $26,610 |
-
What's the price of Context Therapeutics stock today?
One share of Context Therapeutics stock can currently be purchased for approximately $0.88.
-
When is Context Therapeutics's next earnings date?
Unfortunately, Context Therapeutics's (CNTX) next earnings date is currently unknown.
-
Does Context Therapeutics pay dividends?
No, Context Therapeutics does not pay dividends.
-
How much money does Context Therapeutics make?
Context Therapeutics has a market capitalization of 76.87M. Context Therapeutics made a loss 23.96M US dollars in net income (profit) last year or -$0.23 on an earnings per share basis.
-
What is Context Therapeutics's stock symbol?
Context Therapeutics Inc. is traded on the NASDAQ under the ticker symbol "CNTX".
-
What is Context Therapeutics's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of Context Therapeutics?
Shares of Context Therapeutics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Context Therapeutics's key executives?
Context Therapeutics's management team includes the following people:
- Mr. Martin A. Lehr Co-Founder, Chief Executive Officer & Director(age: 41, pay: $250,000)
- Dr. William F. Rencher Ph.D. Head of CMC & Regulatory(age: 66, pay: $246,470)
- Dr. Tarek Sahmoud M.D., Ph.D. Chief Medical Officer(age: 64, pay: $26,610)
-
Is Context Therapeutics founder-led company?
Yes, Context Therapeutics is a company led by its founder Mr. Martin A. Lehr.
-
How many employees does Context Therapeutics have?
As Jul 2024, Context Therapeutics employs 5 workers.
-
When Context Therapeutics went public?
Context Therapeutics Inc. is publicly traded company for more then 3 years since IPO on 20 Oct 2021.
-
What is Context Therapeutics's official website?
The official website for Context Therapeutics is contexttherapeutics.com.
-
Where are Context Therapeutics's headquarters?
Context Therapeutics is headquartered at 2001 Market Street, Philadelphia, PA.
-
How can i contact Context Therapeutics?
Context Therapeutics's mailing address is 2001 Market Street, Philadelphia, PA and company can be reached via phone at +267 225 7416.
Context Therapeutics company profile:
Context Therapeutics Inc.
contexttherapeutics.comExchange:
NASDAQ
Full time employees:
5
Industry:
Biotechnology
Sector:
Healthcare
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a potent and selective antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as anti-estrogen therapies across female hormone-dependent cancers. The company is also developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. The company has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of an anti-claudin 6 bispecific monoclonal antibody for gynaecologic cancer therapy. Context Therapeutics Inc. was incorporated in 2015 and is headquartered in Philadelphia, Pennsylvania.
2001 Market Street
Philadelphia, PA 19103
Philadelphia, PA 19103
CIK: 0001842952
ISIN: US21077P1084
CUSIP: 21077P108
